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Abstract
Biobanking increases the rate at which precision medicine can be used to suc-
cessfully refine currently existing medical treatment methodologies. The purpose 
of precision medicine is to increase a patient’s likelihood of defeating a chronic dis-
ease, by creating a unique and personal treatment method. However, the research 
necessary to develop precision medicine requires thousands of biospecimens, which 
is why biobanking is necessary to move precision medicine forward. Traditional 
biobanks are a library of preserved biological specimens, such as tissue and whole 
blood, that can be later accessed for further testing and analysis. Maintaining these 
types of biobanks is cumbersome and expensive, due to freezer care. Biobank 
samples are used to support therapeutic drug monitoring in clinical trials, epide-
miology, public health screening, and biomarker discovery. Collecting samples for 
large translational studies requires making regular trips to the phlebotomist or a 
clinic, which is an inconvenience that is exacerbated when collecting samples in 
remote and/or resource-limited locations. Inconsistencies in sample collection can 
affect downstream clinical studies. Remedies for these procedural issues include the 
development of a medium that effectively preserves the samples at ambient tem-
perature and developing a virtual biobanking system that allows for long-distance 
access to bioinformatic data of previously analyzed biospecimens.
Keywords: biobanking, precision medicine, dried blood spots (DBS), nucleic acid, 
ambient temperature storage, translational studies
1. Introduction
Biobank acts as a library for genotypic and phenotypic data for a variety of bio-
logical samples. It is the process of acquiring, storing, processing, and distributing 
biological materials for the purpose of clinical use, including for the development of 
precision medicine. The term biobanking covers a broad range of samples, includ-
ing those of animal, plant, and microbial origins. For instance, animal samples can 
be organ tissue, marrow, and synovial fluid, while plants can be roots, leaves, bark, 
flowers, and lastly microbial samples. The biobanking arena has seen significant 
advances from collecting and cataloging samples to having detailed archives of 
genotypic and phenotypic information. The storing of this information is part of 
the newest wave in biobanking, virtual biobanking. Virtual biobanks contain full 
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genomes of previously collected specimen that may be accessed through specialized 
software or portals. Virtual biobanking assists investigators in searching multiple 
sites for specimen worldwide, essentially, allowing for the mining of data remotely 
[1]. Integration of genomics, proteomics, and metabolomics, as well as introduction 
of highly sensitive analysis methods, has translated into a demand for high-quality 
specimens and the need for accurate, reliable, and standardized clinical data. 
However, current methods in collecting samples are strenuous, expensive, and 
unreliable. Samples collected in the field have to be chilled or frozen until analysis, 
but the shipping of large chilled containers and powering freezers are cost limita-
tions affecting research projects. Furthermore, there is a relatively small window of 
time between sample collection, storage, and analysis to preserve sample integrity; 
reducing the reliability of data. As a result, there has been a growing demand in the 
market for developing ambient temperature storage methods. In the following sec-
tions, the relevance of biobanking to precision medicine will be discussed as well as 
advances in sample collection and ambient temperature storage methods to reduce 
the cost of acquiring and storing precious biospecimen.
2. Precision medicine
In the last decade, there has been a push to understand factors that affect an 
individual’s health on the molecular level. These factors include an individual’s 
unique lifestyle and environment because it is now understood that epigenetics 
plays a large role in a person’s health as well as their development of chronic 
diseases, such as cancer [2]. Epigenetics and its effects on multiple “omics” (e.g., 
proteomics) require more than a snapshot of a single person’s life. Instead, large 
data sets ranging from local population (i.e., a neighborhood or city block) to a 
statewide population, or larger, are required to truly understand the connection 
between lifestyle and health; but this is not the only advantage of having a large 
sample size. Determining treatment for a disease requires the largest possible 
sample size, in order to account for all the possible variables that lead to develop-
ing the illness. The marriage of genetic sequencing and external factors that affect 
health (i.e., lifestyle and environmental) is the foundation of precision medicine. 
Precision medicine is the use of multiple facets of an individual’s health to develop 
a unique treatment plan [3] (Figure 1). With the cost of sequencing decreasing, 
it has become possible to query the whole genome in search of variants that are 
known to cause certain disease, and, thus, develop targeted therapies and reduce 
the overall strain placed on the body [4, 5]. Analysis of the human genome in the 
context of diagnostic medicine is one of the main facets of precision medicine. The 
current methodology for designing treatment plans is based on general information 
obtained from clinical trials; however, every person is unique and there are numer-
ous instances where these “umbrella” treatment methods prove to be unsuccessful 
[3]. Thus, by being able to determine the root cause of the disease, be it lifestyle 
affecting gene expression, genetic inheritance of a mutation, or a random mutation 
itself, precision medicine provides the opportunity to have a focused approach in 
diagnostic medicine.
Precision medicine, and the initiative to push it forward, was strongly endorsed 
by the Obama administration after a young woman was able to determine the cause 
of her extremely unusual form of liver cancer through virtual searches of sequenced 
genomes of donors with the same disease [6]. The synergy between genetic mark-
ers and new therapies for cancer treatment is one powerful example of precision 
medicine. Typically, biopsied tissue samples or whole blood samples are used as the 
material for sequencing [6, 7]. For example, liquid biopsies are now routinely used 
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for the analysis of cell-free DNA to look for progression/regression of cancer as 
well as additional genomic mutations [8]. As technology advances, instant inter-
disciplinary integration has become a reality and bioinformatic biobanking makes 
this integration possible [4]. However, there are many instances when hospitals or 
research facilities will not release the sequenced data of the samples that were col-
lected or preserved specimens, and literature sources have inadequate information 
of the biospecimen used [6, 8]. This increases the necessity to have both a national 
and global data base available so that invaluable information could be accessed 
seamlessly. One of the first steps in creating such a large data bank is the develop-
ment of the Million Donor cohort.
Precision medicines’ Million Donor cohort comes with a great responsibility for 
those institutions preserving these samples to answer future research questions [8]. 
The purpose of the cohort is to begin collecting data from one million individuals 
across the nation with diverse backgrounds [3, 9]. Building such a large cohort 
proves to be a daunting task; however, Terry [6] has shown that, when able to, 
patients will take the initiative to be active members in their health maintenance. 
Although questionnaires will be used to develop the cohort data, the success of 
precision medicine depends on the number of available electronic medical records 
(EMRs) to gain valuable insight into quantitative medical data [3]. Developing such 
a sample pool that can be easily accessed requires storing the data in virtual bio-
banks, a topic that will be discussed in detail later in the chapter [9, 10]. Biobanking 
and the accessibility of data with a user-friendly network for the purpose of data 
mining are crucial not only to both short-term and long-term goals of the Precision 
Medicine Initiative but also to the future. Access to samples is necessary to fulfill 
the vision of combining established clinicopathological parameters with emerging 
molecular profiling approaches to create diagnostic, prognostic, and therapeutic 
solutions that are precisely tailored to an individual patient’s unique requirements. 
Sample availability and sample preservation via biobanking are key to the future of 
the Precision Medicine Initiative and beyond.
Figure 1. 
Precision medicine is a holistic approach to treatment where for the first time, the phenotypic, proteomic, 
metabolomic, and the genomic composition of the individual as well as their links to other factors such as the 
microbiome and even the environment will be taken into consideration. This means treating the patient as a 
“whole” in contrast with the current isolated symptom-treatment approach. The goal of precision medicine is to 
develop a personalized treatment regimen, a one-of-a-kind approach that would have a better clinical outcome 
for the patient.
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3. Biobanking
In this section, the growth of biobanking for the purpose of current research 
interests will be discussed. Biobanking has been implemented in the scientific 
community for over 100 years by various institutions worldwide [11, 12]. Biobanks 
are large repertoires of biospecimen, ranging from animal samples to plant and 
microbes, that are used for research purposes [12]. Biobanking itself is a relatively 
simple concept (Figure 2). All types of biospecimen are stored in a biobank for long, 
yet finite amounts of time. These repositories of specimen in traditional biobanks 
remain in large freezers and other storage facilities until needed [12, 13]. Thus, 
biobanks are extremely valuable for translational research studies since generations 
of specimen may be stored and received.
Standardization of samples is key to successful biobanking. Reliability of sam-
ples collected in an ethical and legal manner with the oversight of the Institutional 
Review Board (IRB) or equivalent ethics committee for the biobanking institu-
tions in their respective countries is crucial to ensuring reproducibility of results. 
International standards are being established by both the European Union [14] 
and International Society of Biological and Environmental Repositories (ISBER) 
in the United States [15] to establish standardization metrics for biobanked 
samples. ISBER coordinated the launch of the International Repository Locator 
(IRL) website in early 2015. This centralized locator, analogous to a “repository 
directory,” was created to increase the profile of individual repositories including 
ISBER, researchers, funding bodies, governments, and private industry. However, 
Figure 2. 
Infrastructure needed to biobank samples in a laboratory (left to right). Blood, buccal swab, or tissue biopsy/
aspirate samples collected from donors are transported to the research facility if the collection site is remote 
to the sample processing laboratory. Maintaining traceability and transparency should be mandatory to 
all human samples, the samples are cataloged electronically when received and connected with the donor’s 
electronic health record (EHR) if available, along with other relevant information before either biobanking 
or processing the sample for nucleic acid or other biomolecule (DNA, RNA, buffy coat, proteins) extraction. 
Depending on the size of the donor pool, the most efficient means of processing the large cohort of samples is by 
automation. The biomolecule extracted is analyzed for quantity and quality before storage in a biobank at −80, 
or −196°C (liquid nitrogen). Consequently, for an economical means of storage of a large cohort of samples, the 
extracted biomolecules can be stored in a chemistry matrix for dry state or “glassy state” such as RNA/DNA 
stable (Biomatrica), RNAsecure (ThermoFisher) or GenTegra RNA/DNA (GenTegra LLC) or on treated 
paper such as Whatman FTA or GenSaver or untreated paper such as Whatman 903 or GenCollect. The choice 
of media for storage for biobanking is institute dependent.
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not all facilities with biobanks are willing or able to share these invaluable biospeci-
mens [3, 12, 13]. With such limitations on the use of biobanks, the importance to 
develop new methods for biobanking continues to grow as technology and research 
methods have advanced and become more refined to solve previously, seemingly 
impossible medical mysteries. The Million Donor cohort acts as one solution to the 
problem of free-data sharing since the project’s purpose is to create a comprehen-
sive virtual biobank for the purpose of precision medicine and bettering healthcare 
[3, 16]. Making biobanking a realistic tool and more accessible requires the blend-
ing of specimen collection and analysis.
To streamline biobanking and research analysis, a new concept in biobanking 
is bioinformatic biobanking. This refers to the querying of sequenced genomes 
that have been stored in virtual biobanks. Bioinformatic biobanks are large data-
bases of information pertaining to the sequenced and analyzed specimen [12, 17]. 
In this concept of a biobank, an individual’s immutable genetic markers form a 
library to be queried over a lifetime for continuing patient management. Once a 
sample is analyzed and the data stored, it is then a simple matter of querying the 
data when and as required for specific gene regions, biomarkers, variations, etc. 
This approach is currently being implemented by Helix personal genomics with 
whole genome sequencing as the first step. Using this method negates the need for 
long-term sample storage because the whole genome can be virtually analyzed for 
specific biomarkers that may correlate with a disease. Once the genomic analysis is 
completed, any future test queries involve only a bioinformatic search, as opposed 
to additional sample collection and repeated analysis. This reduces the cost of 
biomedical research significantly; however, the collection, transportation, and 
storage of samples until analysis occurs still pose a significant cost and slow efforts 
in developing a globally available virtual biobank. In the next section, the sample 
types used for biobanking will be discussed, and advances that will eliminate the 
cost of storing and shipping such liquid samples.
3.1 Sample types used for biobanking
The most common sample types collected for precision medicine and biobank-
ing of human specimen are tissue samples and whole blood. Tissue samples can be 
further subdivided into liquid biopsy samples for circulating tumor cells (CTC), 
tissue biopsy samples such as formalin-fixed paraffin-embedded (FFPE) tissue, and 
fresh frozen tissue samples or wet mount tissue slides. Whole blood samples can be: 
peripheral blood mononuclear cells (PBMCs), serum, or plasma. Additional, albeit 
less common, sample types collected are cerebrospinal fluid (CSF), urine, and 
fecal material. When collecting these samples, it will be imperative to have “True 
Control” samples from surrounding disease-free tissue and corresponding known 
disease-state samples for comparisons; but, it is not always practical for tissue 
biopsy samples or CSF. In such instances “external” matched controls must serve as 
acceptable substitutes for “True Control” samples.
3.1.1 Tissue
Tissue samples such as formalin-fixed paraffin-embedded (FFPE) blocks have 
been stored since the early twentieth century. FFPE tissue samples are a common 
sample type collected from biopsies. Although core biopsy samples yield a healthy 
amount of tissue, tissue biopsy procedure is a painful process for the patient and can 
potentially cause considerable trauma to the surrounding tissue. Fine needle aspirate 
(FNA) biopsy with a 21-gauge needle to remove tissue samples for pathology is less 
traumatic to the patient and to the surrounding tissue. Compared to core biopsy 
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samples that are typically about 17 mg or more, the FNA samples are just 2–10 mg 
and the amount of sample that is donated to research is often less than 1 mm as pri-
ority for testing of the biopsy sample is to perform cytopathology. The best outcome 
for nucleic acid-based testing from tissue samples is to isolate nucleic acid from fresh 
or flash-frozen at −196°C tissue samples. There is no ambient temperature method 
available to preserve tissue samples for extracting good-quality nucleic acid.
FFPE is the most common method of preserving tissue samples at ambient 
temperature. FFPE tissue storage has been used for three decades [18] as a means of 
keeping tissue samples at ambient temperature for future research [19, 20]. This has 
created a large resource of pathologically interesting human and animal samples. 
Fixing tissue samples with formalin and embedding in paraffin preserves the 
pathology of the tissue. But formalin fixation can cause both inter and intra protein 
cross-linking [21–23] as well as cross-linking of histones to DNA [24]. Other factors 
affecting the quality of nucleic acid from FFPE samples include buffering formalin, 
time and temperature of fixation and penetration of formalin into the tissue by stasis, 
or by ultrasound, or microwave irradiation. The nucleic acid and protein quality are 
additionally dependent on the time of collection of tissue following postmortem 
interval and cold ischemia. Acceptable time for collection of tissue samples is between 
4 h postmortem and 12 h after cold ischemia has set in. Acceptable time for formalin 
fixation of tissue postmortem is <48 h for RNA [25, 26], <24 h for proteins [27–32], 
and <72 h for DNA [33–36]. It would be best to isolate the nucleic acids from FFPE 
samples within the acceptable time to ensure the best outcome for the quality of the 
nucleic acid isolated. The isolated nucleic acid can be further stored at ambient tem-
perature by removing the aqueous media from the nucleic acid sample or by adding 
some commercially available stabilizers for ambient temperature storage of nucleic 
acid. Although cross-linking of nucleic acid is of concern with aged FFPE samples 
[18, 33], nucleic acid extracted from FFPE samples have been successfully used for 
amplification, single cell analysis, and methylation studies. Decalcification of the 
FFPE sample using EDTA allows for longer PCR product [37], stronger fluorescence 
in situ hybridization (FISH) signals, lower background staining [38], and superior 
comparative genomic hybridization [1] results as compared to other methods.
3.1.2 Blood and blood components
Perhaps the most economical samples are blood samples collected in EDTA tubes 
[35]. A host of specialized blood collection tubes are commercially available for sta-
bilization of transcripts such as Tempus Blood RNA tubes and PAXgene Blood RNA 
tubes [39]. The strategy for storing the samples for short-term usage and long-term 
biobanking needs will determine the quality of the sample. Acceptable short-term 
storage of weeks to months of blood and blood components such as serum, plasma, 
peripheral mononuclear cells (PBMCs) etc. is at 4 to −20°C and long-term storage 
is at −80 to −196°C. Liquid samples such as whole blood, saliva, plasma, and serum 
samples as dried spots can be stored for decades at ambient temperature if sampled 
on chemically treated substrate such as FTA or GenSaver paper cards [40, 41].
Serum and plasma samples can be stored at ambient temperature for extended 
periods of time on chemically treated bead matrix such as GenTegra LLC’s Matrix 
Chaperone (MC) (Figure 3). Up to 250 μL of serum or plasma sample can be 
applied to the MC for storage and for biobanking. Downstream analysis of the MC 
can be performed simply by adding back equivalent volume of water to the MC. The 
full complement of analytes, proteins, enzymes, and nucleic acid in serum and clot-
ting factors in plasma samples (data not shown) have been successfully stored for 
25 days at ambient temperature on MC consisting of a randomly packed chemically 
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treated microsphere wafer when compared to pristine always frozen at −20°C 
serum samples (Table 1).
3.1.3 Dried blood spots microsample biobanking
Dried blood spots (DBSs) can be used for both real-time microsampling and 
subsequent ambient temperature biobanking for epidemiology and biomarker dis-
covery (Figure 4). DBS samples can be particularly effective as a means of sample 
collection from participants in clinical trials. A survey by Tasso Inc. determined that 
a trial candidate may be more compliant to sample collection when given a less pain-
ful option for sample collection such as the OnDemand automated blood collection 
device for DBS collection and when done in the comfort of their own home (data 
unpublished) (Figure 5). Blood stabilized on the DBS can then be mailed by local 
postal services at the patient’s own convenience. Although storage of whole blood 
as DBS is an old technology, historically poor stability outside the lab environment, 
as well as low recovery levels and generally low quality of extracted nucleic acids 
and numerous blood proteins, has hindered its acceptance. In recent years, there 
has been development for a completely new, “smart health care,” paper-based 
sampling technology, which overcomes many of these known drawbacks. Deployed 
as a simple, painless skin prick onto a chemically treated collection card, the dried 
blood may then be recovered by ordinary magnetic bead or column-based DNA 
purification. With the resurgence of interest in the use of DBS for sample collec-
tion, research is being done to develop novel chemistries to yield RNA, DNA, and 
Figure 3. 
Ambient storage of serum samples. It is possible to store the entire complement of biological molecules in serum 
(or any other biological fluids) on a simply made storage device consisting of 2-μm polystyrene beads coated 
with stabilization chemistry collectively called matrix chaperone (MC) for ambient storage and transportation. 
The collection device was a simple three-component device (i), containing a cap (A) with the resuspended 
stabilization chemistry in a matrix of polystyrene beads and the holding chamber (B) with silica gel (C) to 
facilitate drying. A volume of 250 μL of serum sample was added to the cap containing the chemical matrix 
of polystyrene beads (iib) and capped. The assembly was placed in an upside-down position for at least 12 h 
to facilitate drying. To initiate analysis, the sample was reconstituted with 250 μL of water (iic). The sample is 
recovered by transferring the sample to a 1.5-mL tube (iid) and centrifuging the sample at maximum speed for 
a minute (iie). A complete metabolic panel and a lipid panel test were performed on this reconstituted serum 
sample (Table 1).
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proteins with quality and quantity enough to support advanced analytical methods 
such as next generation sequencing and multiplex proteomics.
DBS is also associated with a 100-fold lower carbon footprint, being 100 times 
more compact (in terms of sample size) and it is readily suited for automated 
recovery from such solid-state blood specimens [42]. Long-term storage for 
multiple decades requires storage at −196°C under liquid nitrogen or on treated 
paper such as Whatman® FTA, Ahlstrom-Munksjö GenSaver™ cards. For short-
term storage (weeks to a month), untreated paper such as Whatman 903 paper, 
Ahlstrom-Munksjö GenCollect™ paper, etc. may be used. The paper products work 
by drawing the water out of the sample causing localized dehydration of the sample. 
Specifically treated papers such as Whatman FTA and Ahlstrom-Munksjö GenSaver 
cards further stabilize the sample by either lysis of the cells and/or by prevention 
of various oxidative damage to the sample. Ribosomal RNA (18S and 28S rRNA) 
is more labile when stored in DBS, as demonstrated with a less than ideal RNA 
integrity number (RIN) below 6.5 (RIN values will be explained later on). Storage 
of blood on treated paper is superior to untreated paper for decades-long storage 
of DNA but to date there is no product available for storage of total RNA in whole 
blood for decades other than storing at −196°C.
Advances in non-invasive diagnostics for cancer where routine blood sample 
collection can be used for tracking progression of the disease is much more afford-
able and less painful than a solid tissue biopsy alternative. DBS microsample is a 
good alternative to collecting liquid whole blood in EDTA tubes by phlebotomy 
for individuals where tracking of progression of disease is crucial for prescribing 
treatment options. Advances in the quality and availability of highly sensitive 
Table 1. 
Stability of serum enzymes, proteins, lipids, and metabolites at ambient when stored on the polystyrene 
bead matrix, MC, containing ambient stabilization chemistry for all biomolecules. A volume of 250 μL of 
CAP-certified serum samples spotted on the polystyrene matrix (MC) tubes and dried before storing for 
25 days at ambient. Corresponding control serum samples were stored at −20°C. After 25 days of storage at 
ambient, the experimental and control samples were hydrated with 250 μL of water. All the analytes from 
the rehydrated MC serum samples and the fresh always frozen −20°C control samples were quantified for 
the complete metabolic panel and the lipid panel with the cobas® 6000 analyzer. The percent recovery of the 
analytes was calculated for the ambient stored samples compared to the control serum samples from the initial 
raw values of the test biomolecules. International units per liter (IU/L) of the enzyme panel for alanine amino 
transferase (ALT), aspartate aminotransferase (AST), enzyme marker creatine phosphokinase (CK), amylase, 
and gamma glutamyl transferase (GGT) are within the normal range for the ambient stored serum samples 
when compared to −20°C control samples. The level of the alkaline phosphatase (ALP) was low compared to 
the control serum samples indicating that the stabilizer is not able to protect the labile ALP enzyme. All the 
molecules tested in the protein panel and the lipid panel were in the normal range and maintained at between 
68% and 83% of control indicating stability at ambient of all biomolecules in this panel on the MC. Of the 
three metabolites tested in the metabolic panel, the stabilizing matrix of the serum sample stored at ambient 
could not stabilize the metabolite creatine but cortisol and testosterone were stabilized. Normal ranges for panel 
values were taken from http://www.mayoclinic.org/ (April 3, 2013) except for the testosterone normal range, 
which was taken from https://www.questdiagnostics.com/home/ (January 31, 2020).
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Figure 4. 
Commercially available DBS collection devices for ambient storage and transportation. Biological samples 
collected remotely or stored at designated biobanks can utilize any one of the various products available for 
ambient storage of liquid samples. A number of formats of high-quality fiber-based media are available from 
Ahlstrom-Munksjö, Whatman-Qiagen, and others. The colorless format of cards is ideal for storage of colored 
biological samples such as fecal matter, plants, and whole blood. The colored cards are for storage of colorless 
biological samples such as serum, saliva, and other organics, at ambient. Biosample TFN card, AutoCollect 
card from Ahlstrom-Munksjö and Guthrie card, protein saver card from Whatman-Qiagen are ideal for 
collection of DBS needed for protein and small molecule analysis. The VAMS storage device from Neoteryx™ 
is convenient for patient-centric remote collection of microvolume samples. Some of the collection cards such 
as FTA, GenSaver, GenSaver Color cards and GenPlates are chemically treated for long-term preservation 
of DNA at ambient. These cards are ideal for biobanking and forensics application. AutoCollect card with 
perforated DBS circles are designed for automated sample preparation. GenPlates allow for high-throughput 
automated spotting of biological samples. The Tasso OnDemand collection device with integrated VAMS or 
paper cards is a painless alternative for volumetric collection of DBS. GenSaver, GenPlates, and GenReleaz 
cards allow for the convenience of direct downstream analysis (PCR, NGS, STR, etc.), from a 1-mm punch of 
DBS without any need for sample extraction. The 96-well format is ideal for storage of biobank samples and 
for screening and health monitoring applications. GenSaver 96 color, Indicating CloneSaver and GenPlates are 
designed for high-throughput biobanking needs.
Figure 5. 
Patient survey for acceptance of blood collection method. Convenience, lack of pain, and simplicity of sample 
collection from donor will ensure compliance. As determined from a survey of 146 subjects, by Tasso Inc., on a 
pain scale of 1–10, the surveyed subjects graded the OnDemand device at 1.25, venipuncture at 2.25, and the 
lancet method of blood collection at >3.0. Of the 146 subjects, 83.4% preferred the least painful OnDemand 
method of blood collection compared to 15.9% by the lancet method (data courtesy of Tasso Inc.).
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instruments coupled with the development of software and methodological 
platforms for improved qualitative and quantitative analyses have made adop-
tion of microsampling mainstream [43]. At home, blood collection of finger stick 
blood redundancy on microsampling devices such as GenSaver or FTA paper or on 
polymer compound, for example, Volumetric analytical MicroSampling (VAMS), is 
a convenient and a less painful alternative to phlebotomy. Advances in automation 
of almost pain-free microsampling of blood with the OnDemand by Tasso Inc. or 
Tap by Seventh Sense Biosystems are great alternatives for finger prick collec-
tion. Although opponents of precision medicine [34, 44] argue that matching the 
genotypic and phenotypic makeup of the individual to the treatment will not work, 
thus far, an individual-refined approach to selecting treatments has yielded demon-
strable if still limited success.
3.1.4 Postmortem samples biobanking
Living donors contribute tissue samples only if it is a medical necessity. A 
possible viable source of large quantities of tissue samples is through postmortem 
collection of whole organs and tissues from consenting families. This avenue 
incurs a whole host of new challenges such as the donation consent process, 
recovery of organs and tissues in a limited time frame, postmortem, impact of 
donation on the donor families and steps necessary for creating a postmortem 
biobank such as IRB and registries. Carithers et al. [45] describe development of 
eligibility requirements aligned with scientific needs of the project and imple-
mentation of a successful infrastructure for biospecimen procurement to support 
the prospective collection, annotation, and distribution of blood, tissue, and cell 
lines and associated clinical data from postmortem samples. The development of 
donor eligibility criteria is crucial since limited donor history is available within 
the time frame needed for the collection of potential donor samples as degrada-
tion of biomolecules starts immediately with death. This proposition incurs a 
whole host of new challenges such as the donation consent process, recovery of 
organs and tissues in a limited time frame, postmortem, impact of donation on 
the donor families, and steps necessary for creating a postmortem biobank such 
as IRB and registries.
Sample collection is an intricate process that involves having many facets of the 
process coming together such as participant willingness, maintenance of anonymity 
of the sample source, and collecting samples in an ethically appropriate manner. 
Primarily, sample collection depends on the individual’s willingness to participate in 
the clinical study and their trust in the collecting institution. Higher participation 
rates may be anticipated if the need for the study results is focused on the greater 
good of the community [46]. Often the most problematic aspect of sample collec-
tion when collecting large number of donor samples is maintaining donor anonym-
ity. The Kaiser foundation admits that donor personal information is vulnerable 
and has placed controls to mitigate the issue such as educating the donor as well 
as assigning an alternate identification to donor samples that are for the Precision 
Medicine Initiative [47].
Both private and federally funded institutions have set up repositories to collect 
and archive biological samples to be then made available to researchers globally 
through for-profit, paid services or for free through not-for-profit organizations. 
One such globally recognized institute, the Kaiser Foundation, launched their initia-
tive in October of 2015 and has thus far accumulated over 220,000 samples through 
volunteers with an end goal of collecting a total of 500,000 samples [47, 48]. The 
Kaiser Foundation has the added advantage of possession of the patient’s lifestyle 
and EMRs that can be integrated along with the sample.
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3.1.5 Nucleic acid extraction and storage
The quality and quantity of nucleic acid (DNA and RNA) depends on the quality 
of the nucleic acid in the starting material and the extraction method. There are 
many commercially available kits for extracting nucleic acids from varied sample 
types such as blood, PBMCs, serum, DBS, and fresh or frozen tissue samples. 
Decalcified FFPE samples are treated in the same manner as tissue samples. The 
common mechanism by which most nucleic acid extraction kits work is through 
lysis of the cells to release the nucleic acid followed by capture of the nucleic acid 
in chaotropic agents such as guanidinium salt on paramagnetic silica beads or on 
glass fiber filters. The silica beads or glass fiber filters are then washed to remove the 
proteins and cellular debris leaving relatively clean nucleic acid on the beads/filter. 
The nucleic acid is then released with a buffered elution solution most commonly 
Tris-EDTA at pH 8.3.
Extraction methods or kits must be chosen so they are well suited to the sample 
type [49–52]. Nonetheless, there is varying opinion in the literature regarding the 
choice of nucleic acid extraction kit to use for different sample types. Molteni et al. 
[50] determined that the efficiency of extracting DNA from DBS on plain paper and 
Whatman FTA paper was better with Masterpure kit than with Qiagen’s QIAamp 
Blood mini kit and GenSolve DNA extraction kit (GenTegra LLC) being next best. 
In contrast, Daniels et al. of Broad Institute [52] determined that the efficiency of 
extracting DNA from DBS on Whatman FTA paper was superior with GenSolve 
DNA extraction kit than Qiagen’s QIAamp Blood mini kit. McClure et al. [53] report 
comparable quality of DNA extracted from DBS on Whatman FTA paper with the 
GenSolve DNA extraction kit to that extracted from whole blood samples. These 
DNA samples were compared on the Illumina BovineSNP50 iSelect BeadChip, 
which requires unbound, relatively intact (fragment sizes ≥2 kb), and high-quality 
DNA. Superior-quality total RNA can be extracted with the time-tested phenol 
extraction using the commercially available Tri Reagent, although good-quality 
total RNA can also be obtained by using commercially available RNA extraction kits 
(Zymo Research, Qiagen, and ThermoFisher). Agitation of the DBS sample in lysis 
solution at 40°C ensures more efficient extraction of RNA.
Clearly, the choice of method of nucleic acid extraction is dependent on prior 
sample expertise and analysis methods to be used for the study. A distinction 
between the quantity of nucleic acid extracted vs. the quality of nucleic acid is 
crucial, since having a large quantity of compromised nucleic acid will still result 
in an unsatisfactory outcome (Figure 6). A good check for the quality of DNA and 
RNA is by calculating the DNA Integrity Number (DIN) [54] or the RNA integrity 
number (RIN) [15, 55] of the sample by electrophoresis in the Agilent TapeStation 
or similar devices. Alternatively, the quality of DNA can also be assessed by 
amplification of a 3-kb to 7-kb fragment of a low copy housekeeping gene such as 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [56] and for RNA fragment 
>0.9 kb of a low copy gene such as RNase P [51].
Nucleic acid (both DNA and RNA) extracted from samples can be stored either 
at very low temperatures of −20, −80, or − 196°C or in a dry state by spray dry-
ing; lyophilization; air drying in the presence of commercially available protective 
chemistries such as RNAstable, DNAstable, (Biomatrica Inc., San Diego, CA), 
GenTegra-DNA [57] or GenTegra-RNA (GenTegra LLC, Pleasanton, CA); or by 
spotting on paper. The ribose-phosphate backbone in RNA molecules makes them 
susceptible to degradation. RNA consequently needs to be stored short term at 
−80°C or long term at ultra-low temperature of −196°C or in a precipitated form 
under ethanol. It is also possible to store RNA vitrified in the dry state at ambient 
temperature in the presence of protectants (GenTegra-RNA) that form the “glassy 
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state” to prevent oxidative, hydrolytic, or RNase damage to the ribonucleic acid. The 
protective chemistries also allow the dry nucleic acid to re-dissolve easily because 
the chemistries prevent the formation of the gel-state that pure nucleic acids often 
form at high concentration. The gel-state makes solubilization very difficult without 
using mechanical forces that will also break the nucleic acid strands.
Oxygen and water are essential components in the generation of reactive 
molecules with the degradation process accelerating with increased temperature, 
reduced ionic strength of storage solution, increased concentration of divalent 
cations (greater than 5 ppb) or nucleolytic enzymes. In aqueous solutions (a 
convenient format for storage), nucleic acids are sensitive to depurination, depy-
rimidination, deamination, and hydrolytic cleavage. To inhibit this acid-catalyzed 
degradation of DNA, sample storage solutions for DNA need to be slightly alkaline 
buffered solutions such as tri-buffered to pH of 8.3. Nucleic acid extracted from 
clinical samples likely contain up to 30–40 ppb of iron (from heme or haem). 
Presence of even trace amounts of divalent cations (greater than 5 ppb) increases 
the oxidative degradation of nucleic acid due to the formation of highly reactive free 
radicals via Fenton reaction [58]. Adding chelating agents such as EDTA and EGTA 
to a concentration of 500 mM to the nucleic acid storage solution would ensure that 
the intrinsic divalent cations present in the clinical samples are chelated.
Dry storage of nucleic acids in the presence of protective chemistries causes the 
molecules to lose the ability to diffuse as the sample undergoes a non-crystalline 
Figure 6. 
Quality and quantity of DNA from DBS. A volume of 125 μL of whole blood spotted on GenSaver, GenCollect, 
and Paper F (FTA) paper cards, these were stored for up to 10 years at ambient temperature (A). DNA 
extraction yields obtained from three 6-mm DBS punches of GenSaver and FTA paper cards, the amount 
of DNA obtained from the sample reduces with aging of the DBS. The quality of the DNA is influenced by 
the chemical protective agents added to the card (B). A 7.5-kb fragment of a single copy gene (GAPDH) was 
amplified from 5 ng of DNA from DBS on GenSaver, GenCollect, and FTA cards. DNA in DBS on GenSaver 
cards is 18× more stable than FTA and 4× more stable than GenCollect cards when a 7.5-kb fragment of a 
single copy gene (GAPDH) was amplified by polymerase chain reaction (PCR). A volume of 20 μL of the 
PCR product was subjected to electrophoresis on a 1.2% agarose gel (C). Gel electrophoresis of GAPDH 7.5-kb 
PCR product. Bands showing the PCR product from DBS in lanes 1–3 (GenCollect) and lanes 7–9 (FTA) 
are less intense than those of lanes 4–7 (GenSaver) for the 7.5-kb GAPDH product (D). Gel electrophoresis of 
GAPDH 3.8-kb PCR product. Product on lanes 1–3 comes from GenCollect DBS, product on lanes 4–6 comes 
from GenSaver DBS, products on lanes 7–9 comes from FTA DBS, lane 10 is the negative control and 11 is the 
positive amplification control, the intensities of the PCR product is not distinguishable among paper types. The 
differences in the intensities of the 7.5-kb and the 3.8-kb product indicate that the DNA is better protected from 
environmental effects in GenSaver cards. Samples were run on an E-gel.
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amorphous phase or a “glassy state.” In this dry “glassy state,” the movement of 
protons is expected to be approximately one atomic diameter in 200 years, thus 
preventing both oxidative and nucleolytic degradation of the nucleic acid. Storage 
at ultra-low temperatures of −196°C also vitrified as the water becomes solid ice 
and the molecules lose their ability to move. If moisture is added to the dry sample 
or the temperature is raised in ultra-cooled samples above the glass transition 
temperature of water, DNA/RNA damage can occur as the proton movement and 
reactivity resume [59]. Trace amounts of RNase would also become active upon 
rehydration causing RNA damage.
Successful storage of biomolecules including nucleic acid is ultimately dictated 
by the purity of the extracted material. Highly pure total RNA samples from HeLa 
cells with a RIN of 10 can be stored dry for up to 6 years and 2 months at room 
temperature in GenTegra-RNA (Table 2) without appreciable loss of RNA integrity 
or strand breakage, but rat liver RNA that carries along cellular impurities in the 
extracted total RNA shows degradation of up to 0.2 strand breaks per kilobase, 
deterioration in RIN from 9.0 to 4.0 and a short storage life of 1 year and 8 months. 
Human blood lymphocyte RNA, like rat liver RNA (at an intermediate level of 
residual purity), displays more damage after 4 years as assessed by RIN analysis, 
suggestive of 0.4–0.5 RNA breaks per kilobase after 4 years of ambient temperature 
dry-state storage in GenTegra-RNA. WBC RNA, like rat liver RNA samples stored 
with additional 1 mm of EDTA, incurred much less damage upon 7 months of stor-
age at 56°C (only about 0.1break/kb) (data not shown). RNA strand breakage (X) is 
determined from the calculated RIN value of the aged RNA to the RIN value of the 
unaged RNA stored at −20°C [60].
4. Conclusion
Located in hospitals, universities, non-profit organizations, and pharmaceutical 
companies, biobanks are key infrastructures for research and development; however, 
these vaults for biospecimen are expensive to maintain and are precious samples that 
Table 2. 
HeLa RNA, WBC RNA, and rat liver RNA in water, citrate, or EDTA buffer were stored in GenTegra-RNA 
for 4 years at ambient temperature (25°C). All of the samples were hydrated with water at the end of 4 years. 
RIN scores were analyzed by Bioanalyzer and average strand breaks calculated per kilobase (as determined 
by the negative natural log of ratio of peak heights of 28S-18S) at time equals 4 months to time zero (Rn) for 
the sample groups. The source of RNA and degree of RNase carryover was the key factor in determining the 
maintenance of a stable RIN score and development of number of strand breaks per kb and is independent of 
the type of buffer used for storage of the RNA.
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are not willingly shared. Nonetheless, biobanking provides invaluable insight into 
biomedical mysteries. The long-term translational studies allowed by maintaining 
archives of samples could provide valuable insight for future generations to treat 
chronic diseases. Currently, the research community hopes to use biobanking to push 
forward precision medicine, an initiative set forth by the Obama administration to 
form unique, targeted treatments for each individual [3, 6]. There is a two-fold chal-
lenge for sample collection, ensuring privacy and getting volunteers. Transparency 
and traceability of samples are key to governance of all human biospecimens. Living 
donors contribute tissue samples only if it does not directly affect the quality of their 
life. The development of donor eligibility criteria is crucial since limited donor history 
is available within the time frame needed for the collection of potential donor samples 
as degradation of biomolecules starts immediately with death. Thus, it is incredibly 
important to minimize the amount of time samples spend out of storage, in biobanks.
Biobanking biospecimens is an expensive endeavor both in terms of manpower 
and natural resources used. For example, a single −80°C freezer consumes as much 
energy as a small studio apartment. Most biobanks install a bank of −80°C freezers 
to store the biospecimen samples as each sample needs to be stored for 10 years as 
per CLIA and CAP guidelines. Many institutions store samples for longer than a 
decade for research, test development, and validation purposes. FFPE blocks are 
cataloged at ambient temperature room temperature making them the most effi-
cient way of storing biospecimen samples. Most other sample types are presently 
stored in −80°C freezers for short-term storage or −196°C under liquid nitrogen 
for longer term storage. Although not yet mainstream, advances in microsampling 
analytical technologies has popularized ambient temperature biobanking of whole 
blood, whole blood components, fecal, urine, plasma, and serum biospecimens on 
paper such as treated GenSaver or FTA papers or on VAMS tips or Matrix chaper-
one. Nucleic acid can be stored at ambient temperature in the presence of protective 
stabilizers in a dry state with a choice of commercially available time-tested prod-
ucts such as GenTegra-DNA, GenTegra-RNA, DNAstable, RNAstable, RNAlater, 
etc. Ambient temperature storage is the most economical, environmentally friendly, 
low-carbon footprint, and practical way of storage when long-term storage for 
decades is needed. In addition to reducing molecular mobility, drying the samples 
removes water that can participate in hydrolytic reactions. Furthermore, storing 
samples in a dry state at ambient temperature is independent of environmental 
factors such as electrical supply, temperature, and humidity.
The Precision Medicine Initiative aimed at precisely and rapidly analyzing many 
more cancer genomes will bring about a deeper understanding of cancers fueled by 
discoveries of molecular diagnostic methods. The first fruits of precision medicine are 
already apparent as a wide range of nucleic acid and antibody/protein-based drugs 
have been optimized for individuals with favorable genetic makeup. With a goal of 
collecting a million samples for the Precision Medicine Initiative, storing the samples 
such as blood at −80 or −196°C for prolonged period (decades) is going to become 
impractical at some time. Consideration needs to be given to space and energy require-
ments for such an undertaking. A more practical approach is to consider dry ambient 
temperature storage of biomolecules that have a commercially available solution for 
storage. Although dry storage of nucleic acid and DBS at ambient temperature is an 
economical alternative, adoption of this concept by the research community would 
be a paradigm shift from the time-tested method of preservation by cryogenics. This 
could be due simply to availability of freezers for storing other sample types that yet do 
not have an ambient temperature storage method. A new technology introduced to the 
marketplace has a 30-year adoption cycle and dry storage is a couple decades into that 
cycle with increasing number of research facilities converting to ambient temperature 
storage where applicable. Biobanking of human samples has many ramifications that 
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go beyond the science and technology of their storage. There are national, state, and 
even local regulations that must be met to ensure the protection of individual rights 
and individual privacy. Educating donors on the purpose of biospecimen collection 
and assurance of maintaining the privacy of the donor has favorable outcome. Perhaps 
it is reasonable to consider in a future review these legal and privacy issues.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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